240 publications

Enter search criteria

Fill in keyword(s) to narrow your search.

Fill in a starting date and a closing date for the period your query is about: DD-MM-YYYY

You can select a specific type of a publication you are looking for, such as press releases or speeches

Cetuximab (Erbitux®) for the treatment of metastatic colorectal cancer

Zorginstituut Nederland has carried out a re-assessment of the medicinal product cetuximab (Erbitux®), whereby they came to the ...

Report | 26-06-2017

Acarizax® in cases of allergic rhinitis due to house dust mite

Zorginstituut Nederland carried out an assessment of whether the medicinal product Acarizax® is interchangeable with a drug ...

Report | 26-06-2017

A paradigm shift in perception, learning and action - core of the second advice of the Committee Innovation Health Care Professions & Education

Translation of the core of the second advice of The Committee Innovation Health Care Professions & Education.

Report | 18-05-2017

Tenofovir alafenamide (Vemlidy®) for the treatment of chronic hepatitis B infection

Zorginstituut Nederland carried out an assessment of the medicine tenofovir alafenamide (Vemlidy®). Based on the criteria of the ...

Report | 26-04-2017

Migalastat (Galafold®) for the treatment of Fabry's disease

Zorginstituut Nederland carried out an assessment of whether, based on the criteria of the Medicines Reimbursement System (GVS), ...

Report | 25-04-2017

Elosulfase alfa (Vimizim®) for the treatment of Morquio A syndrome

Zorginstituut Nederland carried out a reassessment of the medicinal product elosulfase alfa (Vimizim®).

Report | 24-04-2017

Ibrutinib (Imbruvica®) for the treatment of chronic lymphatic leukaemia

Zorginstituut Nederland carried out an assessment of the medicinal product ibrutinib (Imbruvica®), for the first-line treatment ...

Report | 24-04-2017

Cysteamine with delayed release (Procysbi®)

Zorginstituut Nederland carried out an assessment of the medicine cysteamine with delayed release (Procysbi®) whereby they ...

Report | 23-03-2017

A paradigm shift in perception, learning and action - summary of the second advice of the Committee Innovation Health Care Professions & Education

Summary of the second report of The Committee Innovation Health Care Professions & Education.

Report | 23-03-2017

Daclizumab (Zinbryta®) for the treatment of relapsing (recidive) forms of multiple sclerosis (RMS)

Zorginstituut Nederland carried out a marginal assessment of the medicine daclizumab (Zinbryta ® ), whereby they came to the ...

Report | 15-12-2016